Results 81 to 90 of about 16,160 (182)

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Valoctocogene roxaparvovec, an adeno‐associated virus (AAV)‐based gene therapy, enables endogenous factor VIII (FVIII) expression in patients with severe hemophilia A without the need for regular FVIII infusions. Long‐term follow‐up assesses durability, safety, and immune‐related challenges following gene therapy.
Kerstin Herbst   +8 more
wiley   +1 more source

Resource Allocation for Energy-Efficient Device-to-Device Communication in 4G Networks

open access: yes, 2014
Device-to-device (D2D) communications as an underlay of a LTE-A (4G) network can reduce the traffic load as well as power consumption in cellular networks by way of utilizing peer-to-peer links for users in proximity of each other.
Alamouti, Sajjad Mehri   +1 more
core   +1 more source

Rights, Pains and Illusions: The Experiences of Welsh‐Speakers at Wales’ ‘Flagship’ Prison

open access: yesThe Howard Journal of Crime and Justice, EarlyView.
ABSTRACT This article challenges claims of ‘inherent’ bilingualism in Wales’ largest prison, HMP Berwyn. Drawing on semi‐structured interviews and extensive documentary research, we find that Welsh‐speaking prisoners at this ‘flagship’ prison have experienced widespread neglect of their needs and overt interferences with their use of the Welsh language.
Robert Jones, Gregory Davies
wiley   +1 more source

SEGB: Security Enhanced Group Based AKA Protocol for M2M Communication in an IoT Enabled LTE/LTE-A Network

open access: yesIEEE Access, 2018
Nowadays machine to machine (M2M) communication and its applications are growing tremendously around the globe as millions of devices are communicating with each other in an Internet of Things (IoT)-enabled long term evolution (LTE)/LTE-advanced (LTE-A ...
Balu L. Parne   +2 more
doaj   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat   +22 more
wiley   +1 more source

Joint Resource Allocation for eICIC in Heterogeneous Networks

open access: yes, 2014
Interference coordination between high-power macros and low-power picos deeply impacts the performance of heterogeneous networks (HetNets). It should deal with three challenges: user association with macros and picos, the amount of almost blank subframe (
Feng, Suili   +3 more
core   +1 more source

Multichannel simultaneous uplink and downlink transmission scheme for flexible duplexing

open access: yesEURASIP Journal on Wireless Communications and Networking, 2017
The idea of adaptive usage of uplink frequency resources for other purposes, such as downlink data transmission, has attracted researchers for many years.
Adrian Kliks, Paweł Kryszkiewicz
doaj   +1 more source

5GNOW: Challenging the LTE Design Paradigms of Orthogonality and Synchronicity

open access: yes, 2012
LTE and LTE-Advanced have been optimized to deliver high bandwidth pipes to wireless users. The transport mechanisms have been tailored to maximize single cell performance by enforcing strict synchronism and orthogonality within a single cell and within ...
Berg, Vincent   +15 more
core   +1 more source

A Hybrid Authentication Protocol for LTE/LTE-A Network

open access: yesIEEE Access, 2019
The wireless technology has revolutionized and had a significant impact on every aspect of people's life. Confidential information, financial transactions, and sensitive conversations are frequent via the wireless network and securing all these data are ...
Jianhong Zhou, Maode Ma, Sanshan Sun
doaj   +1 more source

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy